Pharvaris (NASDAQ:PHVS) Insider Anna Nijdam Sells 1,829 Shares

Pharvaris N.V. (NASDAQ:PHVS) insider Anna Nijdam sold 1,829 shares of the business’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $30.60, for a total transaction of $55,967.40. Following the completion of the transaction, the insider owned 48,945 shares in the company, valued at approximately $1,497,717. The trade was a 3.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anna Nijdam also recently made the following trade(s):

• On Friday, May 22nd, Anna Nijdam sold 5,501 shares of Pharvaris stock. The shares were sold at an average price of $30.74, for a total transaction of $169,100.74.

Pharvaris Stock Up 0.7%

PHVS stock opened at $29.88 on Wednesday. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of -9.40 and a beta of -2.34. Pharvaris N.V. has a 12-month low of $15.46 and a 12-month high of $33.33. The company’s fifty day simple moving average is $28.61 and its 200 day simple moving average is $26.96.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.12. Research analysts expect that Pharvaris N.V. will post -3.25 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Wedbush boosted their target price on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Pharvaris in a research note on Tuesday, March 3rd. Royal Bank Of Canada lowered their price objective on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Citigroup reiterated a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Finally, Citizens Jmp lowered their price objective on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 13th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $49.18.

Institutional Trading of Pharvaris

Several hedge funds have recently modified their holdings of the stock. General Atlantic L.P. increased its stake in shares of Pharvaris by 6.6% in the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after acquiring an additional 500,000 shares in the last quarter. Foresite Capital Management IV LLC increased its stake in shares of Pharvaris by 8.3% in the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after acquiring an additional 368,000 shares in the last quarter. venBio Partners LLC increased its stake in shares of Pharvaris by 8.2% in the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock valued at $115,751,000 after acquiring an additional 350,000 shares in the last quarter. Deerfield Management Company L.P. increased its stake in shares of Pharvaris by 21.1% in the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock valued at $60,939,000 after acquiring an additional 425,000 shares in the last quarter. Finally, Commodore Capital LP increased its stake in shares of Pharvaris by 26.5% in the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after acquiring an additional 507,043 shares in the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.